Cardiovascular morbidity associated with obstructive sleep apnea syndrome;Morbidité cardiovasculaire associée au syndrome d'apnée obstructive du sommeil

Revue des Maladies Respiratoires

Volumn 31, Issue 4, 2014, Pages 375-385

  Destors, M ^a,b,c   Tamisier, R ^a,b,d   Baguet, J P ^c   Levy, P ^a,b,d   Pepin, J L ^a,b,d  

^a UNIV GRENOBLE ALPES   (France)

^b University Grenoble Alpes   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d Clinique de Physiologie   (France)

Author keywords

Cardiovascular risk; Endothelial dysfunction; Hypertension; Hypoxia; Sleep apnoea syndrome

Indexed keywords

ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BYPASS SURGERY; DEPRESSED BLOOD PRESSURE; DISEASE ASSOCIATION; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; INTERMITTENT HYPOXIA; METABOLIC DISORDER; MORBIDITY; OXIDATIVE STRESS; PREVALENCE; PREVENTION; SLEEP; SLEEP DISORDERED BREATHING; VASCULITIS; ADRENERGIC SYSTEM; ANOXIA; BIOSYNTHESIS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COMORBIDITY; COMPLICATION; GLUCOSE INTOLERANCE; METABOLIC SYNDROME X; OBESITY; PATHOPHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; SLEEP APNEA, OBSTRUCTIVE; VASCULAR ENDOTHELIUM;

CARDIOVASCULAR AGENT; NITRIC OXIDE;

ANOXIA; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CEREBROVASCULAR DISORDERS; COMORBIDITY; CONTINUOUS POSITIVE AIRWAY PRESSURE; ENDOTHELIUM, VASCULAR; GLUCOSE INTOLERANCE; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; NITRIC OXIDE; OBESITY; OXIDATIVE STRESS; PREVALENCE; SLEEP APNEA, OBSTRUCTIVE; SYMPATHETIC NERVOUS SYSTEM; VASCULITIS;

EID: 84900854894     PISSN: 07618425     EISSN: 17762588     Source Type: Journal    
DOI: 10.1016/j.rmr.2013.12.003     Document Type: Review

References (60)

1. Peppard PE, Young T, Palta M, et al. Prospective study of theassociation between sleep-disordered breathing and hyperten-sion. N Engl J Med 2000;342: 1378-84.
2. Peker Y, Carlson J, Hedner J. Increased incidence of coronaryartery disease in sleep apnoea: a long-term follow-up. Eur Res-pir J 2006;28: 596-602.
3. Gami AS, Howard DE, Olson EJ, et al. Day-night patternof sudden death in obstructive sleep apnea. N Engl J Med 2005;352: 1206-14.
4. Yaggi HK, Concato J, Kernan WN, et al. Obstructive sleepapnea as a risk factor for stroke and death. N Engl J Med 2005;353: 2034-41.
5. Marin JM, Carrizo SJ, Vicente E, et al. Long-term cardiovascu-lar outcomes in men with obstructive sleep apnoea-hypopnoeawith or without treatment with continuous positive air-way pressure: an observational study. Lancet 2005;365: 1046-53.
6. Tamisier R, Pepin JL, Remy J, et al. 14 nights of intermittenthypoxia elevate daytime blood pressure and sympathetic acti-vity in healthy humans. Eur Respir J 2011;37: 119-28.
7. Somers VK, Dyken ME, Clary MP, et al. Sympathetic neu-ral mechanisms in obstructive sleep apnea. J Clin Invest 1995;96: 1897-904.
8. Hedner J, Darpo B, Ejnell H, et al. Reduction in sympathe-tic activity after long-term CPAP treatment in sleep apnoea:cardiovascular implications. Eur Respir J 1995;8: 222-9.
9. Gilmartin GS, Lynch M, Tamisier R, et al. Chronic intermittenthypoxia in humans during 28 nights results in blood pressureelevation and increased muscle sympathetic nerve activity. AmJ Physiol Heart Circ Physiol 2010;299:H925-31.
10. Ip MS, Lam B, Chan LY, et al. Circulating nitric oxide is sup-pressed in obstructive sleep apnea and is reversed by nasalcontinuous positive airway pressure. Am J Respir Crit Care Med 2000;162: 2166-71.
11. Kraiczi H, Hedner J, Peker Y, et al. Increased vasocons-trictor sensitivity in obstructive sleep apnea. J Appl Physiol 2000;89: 493-8.
12. Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective studyof obstructive sleep apnea and incident coronary heart diseaseand heart failure: the sleep heart health study. Circulation 2010;122: 352-60.
13. Joyeux-Faure M, Stanke-Labesque F, Lefebvre B, et al. Chronicintermittent hypoxia increases infarction in the isolated ratheart. J Appl Physiol 2005;98: 1691-6.
14. Ramond A, Godin-Ribuot D, Ribuot C, et al. Oxida-tive stress mediates cardiac infarction aggravation inducedby intermittent hypoxia. Fundam Clin Pharmacol 2013;27: 252-61.
15. Arnaud C, Poulain L, Levy P, et al. Inflammation contributes tothe atherogenic role of intermittent hypoxia in apolipoprotein-E knock out mice. Atherosclerosis 2011;219: 425-31.
16. Lam JC, Mak JC, Ip MS. Obesity, obstructive sleep apnoea andmetabolic syndrome. Respirology 2012;17: 223-36.
17. Li J, Savransky V, Nanayakkara A, et al. Hyperlipide-mia and lipid peroxidation are dependent on the severityof chronic intermittent hypoxia. J Appl Physiol 2007;102: 557-63.
18. Drager L, Polotsky V. Lipid metabolism: a new frontier in sleepapnea research. Am J Respir Crit Care Med 2011;184: 288-90.
19. Borgel J, Sanner BM, Bittlinsky A, et al. Obstructive sleepapnoea and its therapy influence high-density lipoprotein cho-lesterol serum levels. Eur Respir J 2006;27: 121-7.
20. Meslier N, Gagnadoux F, Giraud P, et al. Impaired glucose-insulin metabolism in males with obstructive sleep apnoeasyndrome. Eur Respir J 2003;22: 156-60.
21. Iiyori N, Alonso LC, Li J, et al. Intermittent hypoxia causes insu-lin resistance in lean mice independent of autonomic activity. Am J Respir Crit Care Med 2007;175: 851-7.
22. Barcelo A, Barbe F, de la Pena M, et al. Insulin resistanceand daytime sleepiness in patients with sleep apnoea. Thorax 2008;63: 946-50.
23. Aron-Wisnewsky J, Minville C, Tordjman J, et al. Chronic inter-mittent hypoxia is a major trigger for non-alcoholic fatty liverdisease in morbid obese. J Hepatol 2012;56: 225-33.
24. Minville C, Hilleret MN, Tamisier R, et al. Nonalco-holic fatty liver disease, nocturnal hypoxia and endo-thelial function in sleep apnea patients. Chest 2014,http://dx.doi.org/10.1378/chest.13-0938 [In press].
25. Oni ET, Agatston AS, Blaha MJ, et al. A systematic review: bur-den and severity of subclinical cardiovascular disease amongthose with nonalcoholic fatty liver; should we care? Atheros-clerosis 2013;230: 258-67.
26. Baguet JP, Hammer L, Levy P, et al. The severity of oxygendesaturation is predictive of carotid wall thickening and plaqueoccurrence. Chest 2005;128: 3407-12.
27. Testelmans D, Tamisier R, Barone-Rochette G, et al. Profile ofcirculating cytokines: impact of OSA, obesity and acute cardio-vascular events. Cytokine 2013;62: 210-6.
28. Minoguchi K, Yokoe T, Tazaki T, et al. Increased caro-tid intima-media thickness and serum inflammatory markersin obstructive sleep apnea. Am J Respir Crit Care Med 2005;172: 625-30.
29. O'Connor GT, Caffo B, Newman AB, et al. Prospective studyof sleep-disordered breathing and hypertension: the SleepHeart Health Study. Am J Respir Crit Care Med 2009;179: 1159-64.
30. Davies CW, Crosby JH, Mullins RL, et al. Case-control studyof 24 hour ambulatory blood pressure in patients with obstruc-tive sleep apnoea and normal matched control subjects. Thorax 2000;55: 736-40.
31. Baguet JP, Boutin I, Barone-Rochette G, et al. Hyper-tension diagnosis in obstructive sleep apnea: self or24-hour ambulatory blood pressure monitoring? Int J Cardiol 2013;167: 2346-721.
32. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Gui-delines for the management of arterial hypertension: the TaskForce for the management of arterial hypertension of the Euro-pean Society of Hypertension (ESH) and of the European Societyof Cardiology (ESC). J Hypertens 2013;31: 1281-357.
33. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasmaaldosterone is related to severity of obstructive sleep apnea insubjects with resistant hypertension. Chest 2007;131: 453-9.
34. Pedrosa RP, Drager LF, Gonzaga CC, et al. Obstructive sleepapnea: the most common secondary cause of hyperten-sion associated with resistant hypertension. Hypertension 2011;58: 811-7.
35. Baguet JP, Barone-Rochette G, Tamisier R, et al. Mechanisms ofcardiac dysfunction in obstructive sleep apnea. Nat Rev Cardiol 2012;9: 679-88.
36. Oldenburg O, Lamp B, Faber L, et al. Sleep-disorderedbreathing in patients with symptomatic heart failure: acontemporary study of prevalence in and characteristics of700 patients. Eur J Heart Fail 2007;9: 251-7.
37. Javaheri S, Shukla R, Zeigler H, et al. Central sleep apnea,right ventricular dysfunction, and low diastolic blood pressureare predictors of mortality in systolic heart failure. J Am CollCardiol 2007;49: 2028-34.
38. Wang H, Parker JD, Newton GE, et al. Influence of obstructivesleep apnea on mortality in patients with heart failure. J AmColl Cardiol 2007;49: 1625-31.
39. Yumino D, Tsurumi Y, Takagi A, et al. Impact of obstructivesleep apnea on clinical and angiographic outcomes followingpercutaneous coronary intervention in patients with acutecoronary syndrome. Am J Cardiol 2007;99: 26-30.
40. Schiza SE, Simantirakis E, Bouloukaki I, et al. Sleep disorderedbreathing in patients with acute coronary syndromes. J ClinSleep Med 2012;8: 21-6.
41. Buchner S, Greimel T, Hetzenecker A, et al. Natural course ofsleep-disordered breathing after acute myocardial infarction.Eur Respir J 2012;40: 1173-9.
42. Arzt M, Young T, Finn L, et al. Association of sleep-disorderedbreathing and the occurrence of stroke. Am J Respir Crit CareMed 2005;172: 1447-51.
43. Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleepapnea-hypopnea and incident stroke: the sleep heart healthstudy. Am J Respir Crit Care Med 2010;182: 269-77.
44. Mehra R, Benjamin EJ, Shahar E, et al. Association of nocturnalarrhythmias with sleep-disordered breathing: the Sleep HeartHealth Study. Am J Respir Crit Care Med 2006;173: 910-6.
45. Gami AS, Pressman G, Caples SM, et al. Association ofatrial fibrillation and obstructive sleep apnea. Circulation 2004;110: 364-7.
46. Ng CY, Liu T, Shehata M, et al. Meta-analysis of obstructivesleep apnea as predictor of atrial fibrillation recurrence aftercatheter ablation. Am J Cardiol 2011;108: 47-51.
47. Garrigue S, Pepin JL, Defaye P, et al. High prevalence ofsleep apnea syndrome in patients with long-term pacing:the European Multicenter Polysomnographic Study. Circulation 2007;115: 1703-9.
48. Hoyos CM, Killick R, Yee BJ, et al. Cardiometabolic changesafter continuous positive airway pressure for obstructivesleep apnoea: a randomised sham-controlled study. Thorax 2012;67: 1081-9.
49. Borel AL, Leblanc X, Almeras N, et al. Sleep apnoea attenuatesthe effects of a lifestyle intervention programme in men withvisceral obesity. Thorax 2012;67: 735-41.
50. Marin JM, Agusti A, Villar I, et al. Association between treatedand untreated obstructive sleep apnea and risk of hyperten-sion. JAMA 2012;307: 2169-76.
51. Pedrosa RP, Drager LF, Amaro AC, et al. Effects of obstruc-tive sleep apnea treatment on blood pressure in patientswith resistant hypertension: a randomized trial. Chest 2013;144: 1487-94.
52. Pepin JL, Tamisier R, Barone-Rochette G, et al. Comparisonof continuous positive airway pressure and valsartan in hyper-tensive patients with sleep apnea. Am J Respir Crit Care Med 2010;182: 954-60.
53. Barbe F, Duran-Cantolla J, Capote F, et al. Long-term effectof continuous positive airway pressure in hypertensive patientswith sleep apnea. Am J Respir Crit Care Med 2010;181: 718-26.
54. Craig SE, Kohler M, Nicoll D, et al. Continuous positiveairway pressure improves sleepiness but not calculated vas-cular risk in patients with minimally symptomatic obstructivesleep apnoea: the MOSAIC randomised controlled trial. Thorax 2012;67: 1090-6.
55. Pepin JL, Chouri-Pontarollo N, Tamisier R, et al. Cheyne- Stokesrespiration with central sleep apnoea in chronic heart failure:proposals for a diagnostic and therapeutic strategy. Sleep MedRev 2006;10: 33-47.
56. Philippe C, Stoica-Herman M, Drouot X, et al. Compliancewith and effectiveness of adaptive servoventilation versuscontinuous positive airway pressure in the treatment ofCheyne-Stokes respiration in heart failure over a six monthperiod. Heart 2006;92: 337-42.
57. Arzt M, Schroll S, Series F, et al. Auto-servo ventilation in heartfailure with sleep apnea - a randomized controlled trial. EurRespir J 2013;42: 1244-54.
58. Buchner NJ, Sanner BM, Borgel J, et al. Continuous positive air-way pressure treatment of mild to moderate obstructive sleep apnea reduces cardiovascular risk. Am J Respir Crit Care Med 2007;176: 1274-80.
59. Barbe F, Duran-Cantolla J, Sanchez-de-la-Torre M, et al. Effectof continuous positive airway pressure on the incidence ofhypertension and cardiovascular events in nonsleepy patientswith obstructive sleep apnea: a randomized controlled trial.JAMA 2012;307: 2161-8.
60. McEvoy RD, Anderson CS, Antic NA, et al. The sleep apneacardiovascular endpoints (SAVE) trial: rationale and start-upphase. J Thorac Dis 2010;2: 138-43.